- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Plans scramble to optimize shifting generic drug costs
This year might be remembered for its generic pipeline, with as many as 37 drugs coming off patent.
Key Points
"With so much money at stake, payers and pharmacy benefit managers are focusing attention on generics," says Leon Edelsack, president, TPG Data Services in Glastonbury, Conn. "When consumers can buy generics for $4, what do they really cost?"
Optimal pricing of generics can be difficult to manage among stakeholders. PBMs' dynamic and discretionary maximum allowable cost (MAC) is often used to price generics at retail, but the information is usually proprietary.
The benchmark for MAC is often the average wholesale price (AWP) minus a percentage discount, ranging widely from 20% to as much as 95%. However, based on information reported by manufacturers, AWPs are often inflated when compared to actual market prices.
"There is no 'correct' price for generics since it depends on utilization, volume, inventory and competition," says Mark Merritt, president and CEO, Pharmaceutical Care Management Assn., the national organization representing PBMs. "Generics are a commodity whose prices move up and down. Aligning all stakeholders is a million-dollar problem."
David Calabrese, vice president, clinical operations, MedMetrics Health Partners, a non-profit PBM, says that a MAC pricing list establishes a standard rate of reimbursement to pharmacies for dispensing, and prices are typically developed after extensive review of standard prices paid by pharmacies to wholesalers.
Unfortunately, many payers are unaware of what PBMs pay retailers and how the PBM determines payment amounts.
"Plans can be caught off guard in signing PBM contracts that have guarantees for generic or MAC pricing that cannot be independently verified," says Craig Stern, founder, Pro Pharmaceutical Consultants Inc.
Richard Bruzak, vice president, pharmacy services for HealthPartners in Minneapolis, says that MAC prices change daily and manufacturers and pharmacies continually change their prices, so reimbursement to providers is on a constant merry-go-round. Not to mention, there are 2,400 generic products on the market, he adds, three times more than a decade ago.
"Our biggest goal is keeping incentives aligned for all stakeholders-having the health plan able to negotiate minimum discounts off AWP with the PBM, and either have dollars at risk for the PBM if they aren't achieved, or have incentives in place if the PBM performs better," Bruzak says. "We stay on top of increases and decreases to remain fair and equitable and build assurances into our contracts."
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More
